FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283367908> ?p ?o ?g. }

• W4283367908 endingPage "e213" @default.
• W4283367908 startingPage "e203" @default.
• W4283367908 abstract "The aim of this retrospective study was to determine the response to a single injection of pegylated asparaginase ('pegaspargase') and to assess the tolerability and outcome of prolonged incorporation of pegaspargase into a modified COP (cyclophosphamide, vincristine, prednisolone) regimen in pegaspargase sensitive cats.Fifty-six client-owned cats with confirmed macroscopic high-grade lymphoma at any anatomical site were included. Treatment was commenced with a single pegaspargase injection. Cats showing an objective response were eligible to continue therapy with pegaspargase incorporated into a modified COP protocol and had their survival analysed using the Kaplan-Meier method and log-rank test.Objective response to pegaspargase was reported in 46 cats (82%), including 21 (38%) complete and 25 (44%) partial responses. Thirty-four responders continued therapy with pegaspargase-COP as the first-line treatment. Of these, 31 cats (92%) achieved complete remission with a median duration of the first remission (disease-free survival [DFS]) of 816 days. The median overall survival time (OST) for all 34 cats treated with pegaspargase-COP was 181 days. Response to the initial pegaspargase injection before COP initiation was significantly associated with DFS (P = 0.04) and OST (P = 0.001). Median DFS/OST for cats with complete response to initial pegaspargase injection was significantly longer compared with those with partial remission (>1273 days/>2066 days vs 77 days/108 days, respectively). Cats with gastric lymphoma showed a significantly longer survival (OST 854 days, 1- and 2-year survival rate 57.1%) compared with cats with intestinal lymphoma (OST 102 days, 1-year survival rate 0%). The pegaspargase-COP protocol was generally well tolerated, but two deaths were likely attributable to treatment-related toxicity during the maintenance phase. Importantly, none of the cats experienced hypersensitivity, despite multiple repeated treatments with pegaspargase.Pegaspargase is an effective agent for feline lymphoma. Its incorporation into a COP chemotherapy protocol may confer a survival benefit, especially in cats with complete response to pegaspargase. Treatment is generally well tolerated, but careful monitoring is recommended. Further studies are required to assess the benefits of pegaspargase as monotherapy or as part of different multi-agent chemotherapy regimens." @default.
• W4283367908 created "2022-06-25" @default.
• W4283367908 creator A5008166503 @default.
• W4283367908 creator A5013116517 @default.
• W4283367908 creator A5042296453 @default.
• W4283367908 creator A5080236529 @default.
• W4283367908 date "2022-06-24" @default.
• W4283367908 modified "2023-10-01" @default.
• W4283367908 title "Pegylated asparaginase in feline high-grade lymphoma: clinical results of single injection and continued incorporation into a modified COP regimen" @default.
• W4283367908 cites W1640338940 @default.
• W4283367908 cites W1947992619 @default.
• W4283367908 cites W1981530380 @default.
• W4283367908 cites W1999722150 @default.
• W4283367908 cites W2005725119 @default.
• W4283367908 cites W2009239857 @default.
• W4283367908 cites W2010566000 @default.
• W4283367908 cites W2014721790 @default.
• W4283367908 cites W2024893955 @default.
• W4283367908 cites W2028340688 @default.
• W4283367908 cites W2037808957 @default.
• W4283367908 cites W2039001517 @default.
• W4283367908 cites W2042706005 @default.
• W4283367908 cites W2045440265 @default.
• W4283367908 cites W2051551724 @default.
• W4283367908 cites W2065154417 @default.
• W4283367908 cites W2068949600 @default.
• W4283367908 cites W2074224206 @default.
• W4283367908 cites W2096844592 @default.
• W4283367908 cites W2113512182 @default.
• W4283367908 cites W2118965650 @default.
• W4283367908 cites W2119238930 @default.
• W4283367908 cites W2121612751 @default.
• W4283367908 cites W2127270733 @default.
• W4283367908 cites W2134716997 @default.
• W4283367908 cites W2136395393 @default.
• W4283367908 cites W2141935028 @default.
• W4283367908 cites W2156945455 @default.
• W4283367908 cites W2158877046 @default.
• W4283367908 cites W2164520862 @default.
• W4283367908 cites W2408843046 @default.
• W4283367908 cites W2926269392 @default.
• W4283367908 cites W3093090760 @default.
• W4283367908 cites W3155294922 @default.
• W4283367908 cites W4231933175 @default.
• W4283367908 cites W4241026884 @default.
• W4283367908 cites W4241364882 @default.
• W4283367908 cites W4242220268 @default.
• W4283367908 cites W4249710322 @default.
• W4283367908 cites W4253206475 @default.
• W4283367908 cites W426270985 @default.
• W4283367908 doi "https://doi.org/10.1177/1098612x221101533" @default.
• W4283367908 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35748790" @default.
• W4283367908 hasPublicationYear "2022" @default.
• W4283367908 type Work @default.
• W4283367908 citedByCount "2" @default.
• W4283367908 countsByYear W42833679082023 @default.
• W4283367908 crossrefType "journal-article" @default.
• W4283367908 hasAuthorship W4283367908A5008166503 @default.
• W4283367908 hasAuthorship W4283367908A5013116517 @default.
• W4283367908 hasAuthorship W4283367908A5042296453 @default.
• W4283367908 hasAuthorship W4283367908A5080236529 @default.
• W4283367908 hasConcept C126322002 @default.
• W4283367908 hasConcept C141071460 @default.
• W4283367908 hasConcept C197934379 @default.
• W4283367908 hasConcept C2776694085 @default.
• W4283367908 hasConcept C2776755627 @default.
• W4283367908 hasConcept C2778375690 @default.
• W4283367908 hasConcept C2779429289 @default.
• W4283367908 hasConcept C2779904517 @default.
• W4283367908 hasConcept C2780073493 @default.
• W4283367908 hasConcept C2781413609 @default.
• W4283367908 hasConcept C71924100 @default.
• W4283367908 hasConcept C90924648 @default.
• W4283367908 hasConceptScore W4283367908C126322002 @default.
• W4283367908 hasConceptScore W4283367908C141071460 @default.
• W4283367908 hasConceptScore W4283367908C197934379 @default.
• W4283367908 hasConceptScore W4283367908C2776694085 @default.
• W4283367908 hasConceptScore W4283367908C2776755627 @default.
• W4283367908 hasConceptScore W4283367908C2778375690 @default.
• W4283367908 hasConceptScore W4283367908C2779429289 @default.
• W4283367908 hasConceptScore W4283367908C2779904517 @default.
• W4283367908 hasConceptScore W4283367908C2780073493 @default.
• W4283367908 hasConceptScore W4283367908C2781413609 @default.
• W4283367908 hasConceptScore W4283367908C71924100 @default.
• W4283367908 hasConceptScore W4283367908C90924648 @default.
• W4283367908 hasIssue "8" @default.
• W4283367908 hasLocation W42833679081 @default.
• W4283367908 hasLocation W42833679082 @default.
• W4283367908 hasOpenAccess W4283367908 @default.
• W4283367908 hasPrimaryLocation W42833679081 @default.
• W4283367908 hasRelatedWork W115168992 @default.
• W4283367908 hasRelatedWork W1499275448 @default.
• W4283367908 hasRelatedWork W1998397384 @default.
• W4283367908 hasRelatedWork W2017047848 @default.
• W4283367908 hasRelatedWork W2121694206 @default.
• W4283367908 hasRelatedWork W2330662417 @default.
• W4283367908 hasRelatedWork W2403331838 @default.
• W4283367908 hasRelatedWork W2409484189 @default.

• next